Compass Pathways plc announced that its Phase 3 COMP006 trial met the primary endpoint for treatment‑resistant depression (TRD). The study compared a 25‑mg dose of COMP360, a proprietary psilocybin formulation, with a 1‑mg dose, both administered three weeks apart. The 25‑mg arm produced a statistically significant reduction in Montgomery‑Åsberg Depression Rating Scale (MADRS) scores at week 6, with a p‑value of less than 0.001 and a clinically meaningful difference of 3.8 points versus the 1‑mg dose.
The 25‑mg dose also demonstrated a rapid onset of effect, with most participants showing improvement the day after administration, and durability that persisted through all measured time points up to week 6. Safety data were encouraging: treatment‑emergent adverse events were mild or moderate and resolved within 24 hours. In the 25‑mg arm, 39 % of participants achieved a ≥25 % reduction in MADRS scores, a threshold considered clinically meaningful. The trial also included a 10‑mg arm, which performed well but was not the primary comparison.
Management emphasized the significance of the results. CEO Kabir Nath said, "Across three robust, well‑designed and well‑executed clinical trials involving more than 1,000 participants, we have now demonstrated consistent, highly statistically significant results at the primary endpoint and a clinically meaningful effect. This is a remarkable achievement for the field of psychiatry – especially in the TRD population, where proving benefit has historically been extraordinarily challenging." He added, "These data strengthen our conviction in the highly differentiated profile for COMP360 and given the urgent need for new treatments in TRD, we are advancing our discussions with the FDA, with the goal of submitting an NDA in Q4 and securing approval." Chief Medical Officer Dr. Guy Goodwin noted, "TRD patients have extremely limited treatment options, and the unmet need remains profound. The promising clinical profile of COMP360 reinforces our belief in its potential to set a new standard of care for this population." Goodwin also remarked, "The latest findings 'redefine rapidity and durability for TRD patients with onset as early as the next day.'" Chief Commercial Officer Lori Englebert described the durability data as "perhaps the most impressive" takeaway of the trial.
Analysts had mixed expectations for the magnitude of the MADRS difference. TD Cowen analysts had a base‑case scenario of a 4‑ to 5‑point reduction, and Compass reported a 3.8‑point difference in COMP006 and a 3.6‑point difference in COMP005. Some analysts viewed the magnitude as modest, especially compared to the placebo‑controlled COMP005 trial, but the comparison in COMP006 was against a 1‑mg dose. Stifel analysts stated that the COMP006 trial "clearly met the Street's bar for success, with overall dataset derisking … approval." Investors reacted strongly, citing the regulatory momentum and the robust efficacy and safety profile.
Future data from the COMP006 trial, including 26‑week results, are expected in early Q3 2026. Compass also highlighted its Breakthrough Therapy designation from the FDA and Innovative Licensing and Access Pathway designation in the UK, which facilitate expedited review. The company’s ongoing discussions with the FDA aim to submit a rolling New Drug Application in Q4, a step that could accelerate market access if approved. The trial’s success reinforces Compass Pathways’ position as a leading developer of psychedelic‑assisted therapies for mental health conditions and underscores the potential for a first‑in‑class treatment for TRD.
The achievement of the primary endpoint in COMP006, combined with the company’s regulatory strategy and the positive market reception, positions Compass Pathways to advance toward approval and commercial launch of COMP360 for treatment‑resistant depression. The data strengthen the company’s case for a rapid regulatory review and highlight the growing acceptance of psychedelic‑based therapeutics in mainstream medicine.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.